vs

Side-by-side financial comparison of Baird Medical Investment Holdings Ltd (BDMD) and Idaho Strategic Resources, Inc. (IDR). Click either name above to swap in a different company.

Idaho Strategic Resources, Inc. is the larger business by last-quarter revenue ($14.6M vs $8.0M, roughly 1.8× Baird Medical Investment Holdings Ltd). Idaho Strategic Resources, Inc. runs the higher net margin — 64.3% vs -142.7%, a 207.0% gap on every dollar of revenue. Idaho Strategic Resources, Inc. produced more free cash flow last quarter ($8.2M vs $-3.2M).

Baird Medical Investment Holdings Ltd is a healthcare-focused investment holding company mainly operating in the Chinese market. It invests in and manages businesses covering in vitro diagnostic devices, medical consumables, and community healthcare services, serving clinical institutions and individual consumers.

Idaho Strategic Resources, Inc. is a U.S.-based natural resource company focused on the exploration, development, and production of critical and strategic minerals. Primarily operating in Idaho, it targets rare earth elements, gold, silver, and other high-demand minerals, supplying products to the clean energy, defense, and industrial manufacturing sectors across North America.

BDMD vs IDR — Head-to-Head

Bigger by revenue
IDR
IDR
1.8× larger
IDR
$14.6M
$8.0M
BDMD
Higher net margin
IDR
IDR
207.0% more per $
IDR
64.3%
-142.7%
BDMD
More free cash flow
IDR
IDR
$11.4M more FCF
IDR
$8.2M
$-3.2M
BDMD

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
BDMD
BDMD
IDR
IDR
Revenue
$8.0M
$14.6M
Net Profit
$-11.4M
$9.4M
Gross Margin
82.1%
68.5%
Operating Margin
-131.3%
62.4%
Net Margin
-142.7%
64.3%
Revenue YoY
92.0%
Net Profit YoY
220.6%
EPS (diluted)
$0.62

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BDMD
BDMD
IDR
IDR
Q4 25
$14.6M
Q3 25
$11.1M
Q2 25
$8.0M
$9.5M
Q1 25
$7.3M
Q4 24
$7.6M
Q3 24
$6.2M
Q2 24
$6.1M
Q1 24
$5.9M
Net Profit
BDMD
BDMD
IDR
IDR
Q4 25
$9.4M
Q3 25
$3.0M
Q2 25
$-11.4M
$2.8M
Q1 25
$1.6M
Q4 24
$2.9M
Q3 24
$1.6M
Q2 24
$2.2M
Q1 24
$2.2M
Gross Margin
BDMD
BDMD
IDR
IDR
Q4 25
68.5%
Q3 25
63.6%
Q2 25
82.1%
57.8%
Q1 25
50.8%
Q4 24
53.3%
Q3 24
48.7%
Q2 24
50.2%
Q1 24
48.1%
Operating Margin
BDMD
BDMD
IDR
IDR
Q4 25
62.4%
Q3 25
23.4%
Q2 25
-131.3%
26.6%
Q1 25
19.3%
Q4 24
36.2%
Q3 24
23.4%
Q2 24
34.2%
Q1 24
36.3%
Net Margin
BDMD
BDMD
IDR
IDR
Q4 25
64.3%
Q3 25
26.8%
Q2 25
-142.7%
29.2%
Q1 25
22.1%
Q4 24
38.5%
Q3 24
25.8%
Q2 24
35.2%
Q1 24
36.8%
EPS (diluted)
BDMD
BDMD
IDR
IDR
Q4 25
$0.62
Q3 25
$0.20
Q2 25
$0.20
Q1 25
$0.12
Q4 24
$0.21
Q3 24
$0.12
Q2 24
$0.17
Q1 24
$0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BDMD
BDMD
IDR
IDR
Cash + ST InvestmentsLiquidity on hand
Total DebtLower is stronger
$8.4M
$2.3M
Stockholders' EquityBook value
$35.6M
$108.2M
Total Assets
$77.0M
$116.2M
Debt / EquityLower = less leverage
0.24×
0.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BDMD
BDMD
IDR
IDR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$6.3M
Q1 24
$5.3M
Total Debt
BDMD
BDMD
IDR
IDR
Q4 25
$2.3M
Q3 25
$3.0M
Q2 25
$8.4M
$3.3M
Q1 25
$3.7M
Q4 24
$1.7M
Q3 24
$2.9M
Q2 24
$2.7M
Q1 24
$3.3M
Stockholders' Equity
BDMD
BDMD
IDR
IDR
Q4 25
$108.2M
Q3 25
$74.3M
Q2 25
$35.6M
$49.3M
Q1 25
$39.8M
Q4 24
$37.7M
Q3 24
$33.1M
Q2 24
$25.4M
Q1 24
$21.6M
Total Assets
BDMD
BDMD
IDR
IDR
Q4 25
$116.2M
Q3 25
$83.1M
Q2 25
$77.0M
$57.7M
Q1 25
$48.1M
Q4 24
$44.0M
Q3 24
$40.8M
Q2 24
$32.2M
Q1 24
$28.7M
Debt / Equity
BDMD
BDMD
IDR
IDR
Q4 25
0.02×
Q3 25
0.04×
Q2 25
0.24×
0.07×
Q1 25
0.09×
Q4 24
0.05×
Q3 24
0.09×
Q2 24
0.11×
Q1 24
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BDMD
BDMD
IDR
IDR
Operating Cash FlowLast quarter
$-3.2M
$10.7M
Free Cash FlowOCF − Capex
$-3.2M
$8.2M
FCF MarginFCF / Revenue
-40.7%
56.0%
Capex IntensityCapex / Revenue
0.6%
17.7%
Cash ConversionOCF / Net Profit
1.15×
TTM Free Cash FlowTrailing 4 quarters
$12.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BDMD
BDMD
IDR
IDR
Q4 25
$10.7M
Q3 25
$2.4M
Q2 25
$-3.2M
$3.5M
Q1 25
$2.4M
Q4 24
$3.2M
Q3 24
$2.5M
Q2 24
$2.6M
Q1 24
$2.6M
Free Cash Flow
BDMD
BDMD
IDR
IDR
Q4 25
$8.2M
Q3 25
$709.8K
Q2 25
$-3.2M
$2.5M
Q1 25
$1.0M
Q4 24
$2.1M
Q3 24
$1.9M
Q2 24
$2.4M
Q1 24
$2.3M
FCF Margin
BDMD
BDMD
IDR
IDR
Q4 25
56.0%
Q3 25
6.4%
Q2 25
-40.7%
26.5%
Q1 25
13.8%
Q4 24
28.0%
Q3 24
30.4%
Q2 24
38.7%
Q1 24
38.3%
Capex Intensity
BDMD
BDMD
IDR
IDR
Q4 25
17.7%
Q3 25
15.3%
Q2 25
0.6%
10.8%
Q1 25
19.4%
Q4 24
13.6%
Q3 24
9.8%
Q2 24
4.3%
Q1 24
5.5%
Cash Conversion
BDMD
BDMD
IDR
IDR
Q4 25
1.15×
Q3 25
0.81×
Q2 25
1.28×
Q1 25
1.50×
Q4 24
1.08×
Q3 24
1.56×
Q2 24
1.22×
Q1 24
1.19×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons